Dr. Kolevzon serves as Clinical Director of Mount Sinai’s Seaver Autism Center and an Associate Professor at Icahn School of Medicine at Mount Sinai.
Dr. Kolevzon has published numerous papers on autism as well as three books designed for medical student and resident education. He has extensive clinical expertise in the psychopharmacology of autism and related conditions and his research is focused on developing new pharmacological treatments as an investigator on many clinical trials. He is also extremely committed to medical student and residency training and education and is the Associate Residency Training Director in Child and Adolescent Psychiatry at Mount Sinai. He is an active teacher, mentor, and clinical supervisor and has received many teaching awards as well as a grant to support innovative educational endeavors.
The Mount Sinai Medical Center, Icahn School of Medicine at Mount Sinai
Every effort has been made to ensure the accuracy of the information in this directory. However some
changes may occur between updates. Please check with your provider to ensure that he or she
participates in your health plan.
Is there any new treatment in the pipeline for autism?
There are several new treatments in the pipeline for autism spectrum disorder. Curemark, LLC recently released positive results from a phase 3 clinical trial of their compound, Luminenz, that is focused on treating symptoms of hyperactivity in Autism. Seaside Therapeutics is also studying Arba...
All Content Posted on This Site is the Responsibility of the Party Posting Such Content. Participation on
This Site by a Party Does not Imply Endorsement of any Other Party’s Content, Products, or Services. Content
Should not be Used for Medical Advice, Diagnosis, or Treatment. see Additional Information.